VKTX
7:05 AM
Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults
Trial Start • Phase 1Trial initiation Wed, Jun 24, 2026vikingtherapeutics.com
Catalyst Calendar
Wed, Jun 24, 2026
1 updatesThu, Jun 11, 2026
1 updatesVKTX
7:05 AM
Thu, May 21, 2026
1 updatesVKTX
7:05 AM
Viking Therapeutics to Participate at Upcoming Investor Conferences
vikingtherapeutics.com
Tue, May 12, 2026
1 updatesVKTX
7:05 AM
Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026
Presentation / Abstract • Phase 2ECO poster presentation Tue, May 12, 2026vikingtherapeutics.com
Tue, May 5, 2026
1 updatesVKTX
7:05 AM
Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026
Presentation / Abstract • Phase 2vikingtherapeutics.com
Wed, Apr 29, 2026
1 updatesVKTX
4:05 PM
Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Enrollment • Phase 3vikingtherapeutics.com
Wed, Apr 22, 2026
1 updatesVKTX
4:35 PM
Viking Therapeutics to Report Financial Results for First Quarter 2026 on April 29, 2026
vikingtherapeutics.com